BioStem Technologies (BSEM) Projected to Post Quarterly Earnings on Wednesday

BioStem Technologies (OTCMKTS:BSEM) is expected to announce its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.50) per share and revenue of $6.3520 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

BioStem Technologies (OTCMKTS:BSEM) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The business had revenue of $6.14 million during the quarter, compared to analysts’ expectations of $5.70 million. On average, analysts expect BioStem Technologies to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

BioStem Technologies Price Performance

Shares of OTCMKTS BSEM opened at $4.09 on Monday. The firm has a market cap of $72.99 million, a PE ratio of -3.67 and a beta of 0.11. BioStem Technologies has a 12-month low of $3.01 and a 12-month high of $10.71. The company’s fifty day simple moving average is $3.68 and its 200 day simple moving average is $4.64.

Analyst Upgrades and Downgrades

Separately, HC Wainwright began coverage on shares of BioStem Technologies in a report on Wednesday, May 6th. They set a “buy” rating and a $9.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, BioStem Technologies presently has an average rating of “Buy” and an average target price of $9.00.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.